|
|
Post by uvula on May 29, 2024 12:50:17 GMT -5
|
|
|
|
Post by porkini on May 29, 2024 13:09:08 GMT -5
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Co PR Newswire Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Wed, May 29, 2024, 8:45 AM EDT5 min read In this article: MNKD -1.94% PULM -0.55% Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease. Master service agreement in place for MannKind to provide future iSPERSE™ dry powder drug formulation development services to Pulmatrix. BEDFORD, Mass., May 29, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD). (PRNewsfoto/Pulmatrix, Inc.) (PRNewsfoto/Pulmatrix, Inc.) Ted Raad, Chief Executive Officer of Pulmatrix, commented, "MannKind's interest in iSPERSE™ validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind's Cricket® device to develop the 1st orally inhaled DHE treatment for acute migraine." The Company entered into a cross license with MannKind pursuant to which MannKind will grant Pulmatrix a perpetual, royalty free, exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of PUR3100, our proprietary formulation of dihydroergotamine (DHE) with iSPERSE™, and a perpetual, royalty free, non-exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of any dry powder formulation formulated for the treatment or prevention of neurological disease. As part of the cross-license, the Company will grant MannKind a perpetual, royalty free, exclusive license to formulate iSPERSE™ with clofazimine for inhalation by humans for the treatment or prevention of infection, for the treatment or prevention of nontuberculous mycobacteria lung disease in humans, and with insulin for inhalation by humans for the treatment or prevention of diabetes. We will also grant MannKind a perpetual, royalty free, non-exclusive license to formulate iSPERSE™ for inhalation for the treatment or prevention of endocrine disease and for inhalation for the treatment or prevention of interstitial lung diseases (including IPF, PPF and other related lung diseases) in humans ("ILD"). As part of the transaction, MannKind will assume the lease of our Bedford, Mass., R&D facility along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory. To maintain continuity of iSPERSE™ platform knowledge, MannKind plans to hire some members of the Pulmatrix R&D staff. The agreements are anticipated to close in July 2024. About Pulmatrix, Inc. Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat central nervous system ("CNS"), respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for CNS disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes For Afrezza, I recall there being talk about a "2U" cartridge for peds or correction dosing. Was there also talk about making larger dose units rather than using multiple cartridges? I was also noticing "insulin for inhalation by humans for the treatment or prevention of diabetes." This seems to be a new description from the top down. That has been discussed on this board though. |
|
|
|
Post by MnkdWASmyRtrmntPlan on May 29, 2024 13:14:42 GMT -5
wow, that's interesting, sayhey. And according to this, he also invented Afrezza. HuSol Steiner, PhD, Chairman, has founded three public companies (CTAI now EMIS, PDC now MNKD, & BIOD) and two private companies, Perosphere Pharmaceuticals, (sold to AMAG for $615 million in aggregate) and Perosphere Technologies. He invented AMAG’s rescue drug, ciraparantag, Biodel’s Ultra-rapid insulin, MannKind’s Afrezza & MedTone Inhaler. casspharma.com/about-usOr, was that just a misstatement like that Al Gore invented the internet. I thought migraine-treatment was on the shelf and ready to be deployed whenever Mike ever gets around to it. I didn't know they had a molecule developed for it, like with GLP1. It's a shame to give up that future candidate, but it doesn't seem like Mike intends on getting around to it anyway. I agree again, sayhey, that I think they should stay more focused and on-track with what they have and speed them up as quickly as possible. Maybe iSphere is easier and/or faster to get ready for market than TS. |
|
|
|
Post by ktim on May 29, 2024 14:03:05 GMT -5
I think it's iSPERSE (think dispersion, not spherical). Haven't a clue why there's an "i"... might as well have added 2.0 to the end of it if they wanted to sound techie. Maybe they need to hype a Bluetooth extension for iSPERSE... a Bluetooth enabled internet of dispersion particles  Mike could do an add-on licensing deal for that. Wonder which operating system iSPERSE uses. |
|
|
|
Post by letitride on May 29, 2024 14:22:31 GMT -5
Clofazimine may end up in a cricket, as well as larger doses of Afrezza, seems like the cricket may learn to fly.
|
|
|
|
Post by celo on May 29, 2024 15:22:51 GMT -5
I just hope there was some due diligence on the iSperse particle and the future of using their lab.
Mannkind is in such a great financial position and maintaining a continual positive cash flow is incredibly important to us as share holders. No more cash losses. The advertising for Afrezza and purchase of V=go were cash losses.
Bad bets when this company didn't need them. I think this stock is still suffering around some of those bad decisions and of course the surprise Christmas stock sale. Weariness based on our history, when we are on the verge of building great momentum, would be another disappointment in a long line of them.
New corporate shareholders won't take it.
Mannkind better have got this right. Can not tell from a couple press releases. But they better not be shooting from the hip, which has been done in the past.
|
|
|
|
Post by letitride on May 29, 2024 16:35:40 GMT -5
Waiting for MNKD-501 update would love to know if this expedites its progress.
|
|
|
|
Post by Thundersnow on May 29, 2024 18:19:58 GMT -5
Here is my negative spin: 1. More mouths to feed. 2. The initial attempt to technospherize clofazimine failed because they couldn't deliver enough of the drug with the cricket inhaler. 1. Typically when a company expands, it has to feed more mouths. Just how it works. I take it you’d rather MannKind remain small. I don’t, and thank goodness MannKind doesn’t either! 2. MannKind has never said that. Will you please provide the source for your information? MannKind is using a nebulized formulation of clofazimine that has been fast tracked by FDA. Mike has mentioned the R&D team tinkering with a Technosphere version, but has never once mentioned Cricket that I am aware of. In fact, we never use the Cricket, only the Dreamboat. Cricket is meant to be a one time single use device. Dreamboat is reusable and totally different design. We’re out licensing something we don’t even utilize. I believe this was a great deal and look forward to seeing what happens with this. If MannKind, who is an expert in dry powder formulation and drug delivery, believes this is a good powder to acquire for future drug development, then I’ll take their word for it. It's possible the Dreamboat cartridge is too small to handle the large dosage of Clofazimine and maybe with the cricket device it has a larger capacity to hold the drug. Also the PR said that ISPERSE may be used for insulin production. Maybe MNKD is looking to make a larger size Afrezza?? Maybe diabetics are tired of using multiple cartridges? I can see a 24U or 36U Cartridge. The question is......can the Dreamboat handle the larger dosage or will they develop a new Dreamboat? |
|
|
|
Post by Thundersnow on May 29, 2024 18:28:20 GMT -5
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Co PR Newswire Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Wed, May 29, 2024, 8:45 AM EDT5 min read In this article: MNKD -1.94% PULM -0.55% Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease. Master service agreement in place for MannKind to provide future iSPERSE™ dry powder drug formulation development services to Pulmatrix. BEDFORD, Mass., May 29, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD). (PRNewsfoto/Pulmatrix, Inc.) (PRNewsfoto/Pulmatrix, Inc.) Ted Raad, Chief Executive Officer of Pulmatrix, commented, "MannKind's interest in iSPERSE™ validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind's Cricket® device to develop the 1st orally inhaled DHE treatment for acute migraine." The Company entered into a cross license with MannKind pursuant to which MannKind will grant Pulmatrix a perpetual, royalty free, exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of PUR3100, our proprietary formulation of dihydroergotamine (DHE) with iSPERSE™, and a perpetual, royalty free, non-exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of any dry powder formulation formulated for the treatment or prevention of neurological disease. As part of the cross-license, the Company will grant MannKind a perpetual, royalty free, exclusive license to formulate iSPERSE™ with clofazimine for inhalation by humans for the treatment or prevention of infection, for the treatment or prevention of nontuberculous mycobacteria lung disease in humans, and with insulin for inhalation by humans for the treatment or prevention of diabetes. We will also grant MannKind a perpetual, royalty free, non-exclusive license to formulate iSPERSE™ for inhalation for the treatment or prevention of endocrine disease and for inhalation for the treatment or prevention of interstitial lung diseases (including IPF, PPF and other related lung diseases) in humans ("ILD"). As part of the transaction, MannKind will assume the lease of our Bedford, Mass., R&D facility along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory. To maintain continuity of iSPERSE™ platform knowledge, MannKind plans to hire some members of the Pulmatrix R&D staff. The agreements are anticipated to close in July 2024. About Pulmatrix, Inc. Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat central nervous system ("CNS"), respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for CNS disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes It looks like PULM wants to use the cricket device for their migrane drug. Makes sense.......No need for cartridges. Having a predetermined disposable device full of their drug and people can slip it into their pockets. CARRY N GO!! |
|
|
|
Post by Thundersnow on May 29, 2024 18:29:49 GMT -5
|
|
|
|
Post by Thundersnow on May 29, 2024 18:31:12 GMT -5
What are we doing here? We are out-licensing MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine (DHE) for migraine treatment. The cricket is for Technosphere. Is Pulmatriz planning on putting DHE on Technosphere? What molecule was it Al Mann was using for migraines? Sumatriptan |
|
|
|
Post by Thundersnow on May 29, 2024 18:35:02 GMT -5
If I like this deal, does that mean I am a traitor to Al Mann? Al didn't invent Technosphere. Sol Steiner did. I am not clear what this deal is about. It seems iSpherse does not work so well with their DHE treatment for acute migraine but Technosphere might and it seems that clofazimine doesn't work so well with Technosphere but may work better with iSpherse? I guess we all kind of figured they had issues putting clofazimine on TS so maybe iSpherse helps? Who knows maybe iSpherse would work better with Saxenda but Al Mann had some pretty great results putting native GLP1 on Technosphere. I am not sure I like paying for more R&D when we need to do the afrezza GLP1 trial and we need to do the Saxenda DPI trails. I also thought we had already put something on TS for migraines and had some good initial results but I don't remember what happened here. I just hope we are not signing up for another boondoggle. >>I am not clear what this deal is about. It seems iSpherse does not work so well with their DHE treatment for acute migraine but Technosphere might and it seems that clofazimine doesn't work so well with Technosphere but may work better with iSpherse?<< No one said DHE does not work with iSPHERE. My interpretation is that PULM needed a better inhaler and wants to use the Cricket. |
|
|
|
Post by uvula on May 29, 2024 18:43:08 GMT -5
Nice video. I'm glad Martine went with mnkd instead of Pulm. |
|
|
|
Post by mymann on May 29, 2024 18:54:25 GMT -5
iSperse molecule might give Technosphere a serious competition in the future.
|
|
|
|
Post by Thundersnow on May 29, 2024 19:00:29 GMT -5
Looks like PULM is on Life Support. They are putting all of their eggs in one basket.
About PUR3100
PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine. The Phase 1 PUR3100 trial results were presented at the 65th Annual Meeting of the American Headache society in June 2023. Over 38 million patients suffer from migraine in the United States and there is currently no orally inhaled DHE treatment option for patients.
|
|
Mike could do an add-on licensing deal for that. Wonder which operating system iSPERSE uses.
